Q-omics provides the consensus-scored NIP7P3 profile across patient tissues and cancer cell-line models. NIP7P3 expression is associated with patient survival in 17 of 34 cancer types, with the highest sampling consensus in BRCA. Among the 18 cancer types available for tumor–normal comparison, NIP7P3 is differentially expressed in 6, with the highest sampling consensus in KIRP. Additionally, NIP7P3 RNA expression shows 14,607 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight BRCA, KIRP, and GBM as cancer lineages where NIP7P3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for NIP7P3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes NIP7P3 survival associations across molecular data types. NIP7P3 RNA expression shows survival associations in the most cancer types (17). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible NIP7P3 RNA expression–survival associations across cancer types. High NIP7P3 expression shows unfavorable associations in THCA, LUSC and COAD, but favorable associations in BRCA, LIHC and LUAD. The BRCA Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .001). Together, the overview and detailed table identify BRCA as the clearest survival context for NIP7P3 RNA expression.
This table summarizes NIP7P3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 6. The strongest signals are observed in KIRP for RNA.
This table ranks reproducible tumor–normal expression differences for NIP7P3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. NIP7P3 shows lower tumor expression in KIRP and THCA and higher tumor expression in STAD, BRCA, LUAD and HNSC. The KIRP box plot shows higher NIP7P3 RNA expression in normal versus tumor tissue (log2 FC = −0.052, t-test p = .018).
This table shows molecular features associated with NIP7P3 in patient tissues and cancer cell lines. In patient samples, NIP7P3 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set.
